Scott Kathleen D. 4
4 · ARS Pharmaceuticals, Inc. · Filed Aug 22, 2025
Insider Transaction Report
Form 4
Scott Kathleen D.
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-08-21$15.00/sh−12,500$187,500→ 10,042 total - Exercise/Conversion
Common Stock
2025-08-21$1.50/sh+12,500$18,750→ 22,542 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-08-21−12,500→ 739,830 totalExercise: $1.50Exp: 2032-02-29→ Common Stock (12,500 underlying)
Holdings
- 8,250(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025.
- [F3]Immediately exercisable.